WednesdayDec 27, 2017 1:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018

DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of…

Continue Reading

TuesdayDec 26, 2017 2:38 pm

NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRA: IN9) Completes Private Placement, Will Use Proceeds for Neuenergy® Marketing

Neuenergy is a chewable and revolutionary energy tablet powered by blueberries and anti-oxidants with no sugar or calories NeutriSci International names Glen Rehman as new CEO Company sees new opportunities for its product in the cannabinoid field, as well as new strategic partnerships NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRANKFURT: IN9) recently announced that it has raised $499,999.95 in a non-brokered private placement (http://cnw.fm/C4cA1), with the proceeds to be used for marketing and advertising of Neuenergy®, its branded blueberry-powered energy chewable tablet (http://cnw.fm/Ll6n9). Funds will also go to the company for general corporate purposes. In addition, the company announced…

Continue Reading

FridayDec 22, 2017 10:26 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017…

Continue Reading

TuesdayDec 12, 2017 2:24 pm

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Aims to Enhance Opioid Analgesic Effects with Specific Cannabis Strain

Unique scientific approach lends more credibility and increases consumer confidence Huge potential for cannabis to replace opioids as analgesics Strategic partnerships position Veritas strongly in the medical cannabis industry On September 13, 2017, Cannevert Therapeutics Ltd. ("CTL"), the research arm of Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), filed a provisional patent for the use of a specific strain of cannabis to enhance the actions of opioid analgesics. Opioid analgesics are traditionally prescribed for relief of acute and chronic pain. However, over-prescription or prolonged use can lead to addiction. Recreational users of opioids commonly run the risk of…

Continue Reading

FridayDec 08, 2017 11:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as…

Continue Reading

WednesdayDec 06, 2017 12:03 pm

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Providing Clinical Proof of Cannabis Efficiency

Veritas Pharma is unlocking the science underlying medical cannabis Clinically profiling select cannabis strains - pharmacologically identifying strains for specific disease conditions Entering human clinical studies with valuable IP’s in place There is growing support for medicinal cannabis. Repeated peer-reviewed studies have demonstrated positive patient responses in a variety of maladies. However, to date, the response has been largely anecdotal, and, unlike rigorous pharmacology, the precise mechanisms and chemical profiles of cannabinoids remain unknown.  Through exacting scientific protocols, Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is about to radically change the understanding and applications of this millennia-old medicine.…

Continue Reading

MondayDec 04, 2017 9:21 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

Major interest generated in Lexaria’s technology at MJBizCon Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977